Biotechs are strategically using Australia's speed to their advantage. By starting a Phase 1 trial in Australia in parallel with a US IND application, they can collect early data from healthy volunteers and a small patient cohort. This data can then be used to strengthen the US filing, potentially justifying a higher starting dose or an improved trial design.

US biotechs increasingly use sites like Australia to accelerate development, as Create Medicines did by moving from concept to clinic in under 12 months. What was once viewed with suspicion is now a key strategy to generate data faster and more cheaply, competing with the speed of China's ecosystem.

The US regulatory regime for early clinical trials is so slow that companies are opting for more efficient systems, like Australia's local IRB-based approval. This offshoring of initial research puts the US at a global competitive disadvantage in generating crucial early data.

The global landscape for early-stage clinical trials is shifting, with the U.S. at risk of falling behind. Australia has established itself as a trendsetter and a primary destination for first-in-human studies, while China is accelerating development by leveraging "China speed" and a higher regulatory risk tolerance.

A treaty between the FDA and Brazil's health department allows clinical trials conducted in Brazil to be accepted by the FDA. This provides a pathway for biotech startups to drastically reduce R&D costs and accelerate timelines without compromising the "gold standard" of US regulatory approval.

The current unpredictability at the FDA is so pronounced that prominent biotech investor Peter Kolchinsky of RA Capital is now advising his portfolio companies to de-risk development by conducting early-stage clinical trials outside the United States. This marks a significant strategic shift for US-based innovators.

Moving first-in-human studies to countries like Australia and China is now a core business strategy, not just a cost-saving measure. It allows U.S. biotechs to navigate a more flexible regulatory environment and accelerate development timelines.

U.S. FDA requirements for early-stage trials, particularly safety margins, are considered ill-suited for genetic medicines, prompting companies to look abroad. The UK is emerging as a preferred destination, with its regulator, the MHRA, actively creating incentives and faster pathways to attract these innovative clinical programs.

Top biotech VC Bob Nelsen contends the U.S.'s competitive edge is eroding because of slow, burdensome FDA processes. He points to Australia's model, where human trials can be approved in days, as the standard the US must adopt to compete with agile global players like China.